These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

712 related articles for article (PubMed ID: 31200861)

  • 21. Discovery of E3 Ligase Ligands for Target Protein Degradation.
    Lee J; Lee Y; Jung YM; Park JH; Yoo HS; Park J
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accelerating PROTAC drug discovery: Establishing a relationship between ubiquitination and target protein degradation.
    Gross PH; Sheets KJ; Warren NA; Ghosh S; Varghese RE; Wass KWass KE; Kadimisetty K
    Biochem Biophys Res Commun; 2022 Nov; 628():68-75. PubMed ID: 36084553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in designing ternary complexes: Integrating in-silico and biochemical methods for PROTAC optimisation in target protein degradation.
    Shaik S; Kumar Reddy Gayam P; Chaudhary M; Singh G; Pai A
    Bioorg Chem; 2024 Dec; 153():107868. PubMed ID: 39374557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Small-Molecule Degraders beyond PROTACs-Challenges and Opportunities.
    Kastl JM; Davies G; Godsman E; Holdgate GA
    SLAS Discov; 2021 Apr; 26(4):524-533. PubMed ID: 33632029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methods for computer-assisted PROTAC design.
    Rovers E; Schapira M
    Methods Enzymol; 2023; 690():311-340. PubMed ID: 37858533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PROTACs- a game-changing technology.
    Konstantinidou M; Li J; Zhang B; Wang Z; Shaabani S; Ter Brake F; Essa K; Dömling A
    Expert Opin Drug Discov; 2019 Dec; 14(12):1255-1268. PubMed ID: 31538491
    [No Abstract]   [Full Text] [Related]  

  • 27. PRosettaC: Rosetta Based Modeling of PROTAC Mediated Ternary Complexes.
    Zaidman D; Prilusky J; London N
    J Chem Inf Model; 2020 Oct; 60(10):4894-4903. PubMed ID: 32976709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs.
    Maneiro M; De Vita E; Conole D; Kounde CS; Zhang Q; Tate EW
    Prog Med Chem; 2021; 60():67-190. PubMed ID: 34147206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New strategy for renal fibrosis: Targeting Smad3 proteins for ubiquitination and degradation.
    Wang X; Feng S; Fan J; Li X; Wen Q; Luo N
    Biochem Pharmacol; 2016 Sep; 116():200-9. PubMed ID: 27473774
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent Advances in PROTACs for Drug Targeted Protein Research.
    Yao T; Xiao H; Wang H; Xu X
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PROTAC-DB: an online database of PROTACs.
    Weng G; Shen C; Cao D; Gao J; Dong X; He Q; Yang B; Li D; Wu J; Hou T
    Nucleic Acids Res; 2021 Jan; 49(D1):D1381-D1387. PubMed ID: 33010159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Development of Protein Knockdown Technology as Emerging Drug Discovery Strategy].
    Ohoka N
    Yakugaku Zasshi; 2018; 138(9):1135-1143. PubMed ID: 30175757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The importance of cellular degradation kinetics for understanding mechanisms in targeted protein degradation.
    Riching KM; Caine EA; Urh M; Daniels DL
    Chem Soc Rev; 2022 Jul; 51(14):6210-6221. PubMed ID: 35792307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CDK Family PROTAC Profiling Reveals Distinct Kinetic Responses and Cell Cycle-Dependent Degradation of CDK2.
    Riching KM; Schwinn MK; Vasta JD; Robers MB; Machleidt T; Urh M; Daniels DL
    SLAS Discov; 2021 Apr; 26(4):560-569. PubMed ID: 33190579
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery.
    Xi JY; Zhang RY; Chen K; Yao L; Li MQ; Jiang R; Li XY; Fan L
    Bioorg Chem; 2022 Aug; 125():105848. PubMed ID: 35533582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High throughput E3 ligase degron binding assays for novel PROTAC ligand discovery.
    Guenette RG; Potts PR
    Methods Enzymol; 2023; 681():23-39. PubMed ID: 36764759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteolysis-targeting chimeras: A promising technique in cancer therapy for gaining insights into tumor development.
    Lv M; Hu W; Zhang S; He L; Hu C; Yang S
    Cancer Lett; 2022 Jul; 539():215716. PubMed ID: 35500825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted protein degradation: elements of PROTAC design.
    Paiva SL; Crews CM
    Curr Opin Chem Biol; 2019 Jun; 50():111-119. PubMed ID: 31004963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras.
    Wang Y; Han L; Liu F; Yang F; Jiang X; Sun H; Feng F; Xue J; Liu W
    Colloids Surf B Biointerfaces; 2020 Apr; 188():110795. PubMed ID: 31991291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta.
    Bai N; Miller SA; Andrianov GV; Yates M; Kirubakaran P; Karanicolas J
    J Chem Inf Model; 2021 Mar; 61(3):1368-1382. PubMed ID: 33625214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.